Chemistry:Sibrotuzumab
From HandWiki
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | FAP |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
(what is this?) (verify) |
Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP[1][2]
In 2003 it failed a phase II clinical trial for metastatic colorectal cancer.[3]
References
- ↑ "A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer". Clinical Cancer Research 9 (5): 1639–47. May 2003. PMID 12738716.
- ↑ "Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients". Investigational New Drugs 22 (1): 39–52. January 2004. doi:10.1023/B:DRUG.0000006173.72210.1c. PMID 14707493.
- ↑ "Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer". Onkologie 26 (1): 44–8. February 2003. doi:10.1159/000069863. PMID 12624517.
Original source: https://en.wikipedia.org/wiki/Sibrotuzumab.
Read more |